Dr. Welling on the Efficacy of Nivolumab in HCC

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at NYU Langone Health's Perlmutter Cancer Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

The initial findings of CheckMate-040 show that nivolumab was well tolerated and safe. The toxicity profile is better than what is seen currently with other agents, explains Welling. There have been significant responses seen with all subsets of patients.

There have been durable responses, states Welling. The data are still being analyzed to determine what the overall survival will be with the cohorts. Ongoing studies are being conducted to compare nivolumab with other agents.

Related Content:

OncLive TVImmuno-OncologyGastrointestinal Cancer
OncLive’s September Roundup of Key FDA Approvals in Oncology
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer